hIL23A/hTL1A(3)

Fig.1 In Vivo Efficacy of Risankizumab and Duvakitug combo in TBNS-induced acute colitis in Humanized hIL23A/hTL1A(3) Mouse Model

(A) Body weight change and (B) DAI score in the TBNS-induced acute colitis model of hIL23A/hTL1A(3) mice. In this study, all hIL23A/hTL1A(3) mice were randomly divided into experimental and control cohorts groups on Day -1. The acute colitis model was established in hIL23A/hTL1A(3) mice by a single intrarectal injection of 1.5% TNBS on Day 0. Body weight and DAI score were recorded daily. (n=4-5 males per group, 9-10 weeks old, Mean ± SEM, one-way ANOVA followed by Dunnett's multiple comparison test, *P<0.05, **P<0.01, ***P<0.0001)

Fig.2 In Vivo Efficacy of Risankizumab and Duvakitug combo in TBNS-induced acute colitis in hIL23A/hTL1A(3) Mouse Model.

(A) Colon length. (B) Colon weight. (C）Colon index. On Day 5, all mice were sacrificed, and the isolated colons were subjected to weight, length and photograph. The results demonstrated that, compared with the control group, combo treatment groups exhibited a significant amelioration of TBNS-induced acute colitis in hIL23A/hTL1A(3) mice. (n=4-5 males per group, 9-10 weeks old, Mean ± SEM, one-way ANOVA followed by Dunnett's multiple comparison test, *P<0.05, **P<0.01, ***P<0.001, ****P<0.0001)

Fig.3 In Vivo Efficacy of Risankizumab and Duvakitug combo in TBNS-induced acute colitis in hIL23A/hTL1A(3) Mouse Model.

Colon photo.  On Day 5, all mice were sacrificed, and the isolated colons were subjected to weight and photograph. The results demonstrated that, compared with the control group, treatment groups exhibited a significant amelioration of TBNS-induced acute colitis in hTL1A mice. (n=4-5 males per group, 9-10 weeks old)